Association of genetic risk of Alzheimer’s disease and cognitive function in two European populations DOI Creative Commons
Biqi Wang, Lori B. Chibnik, Seung Hoan Choi

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Фев. 21, 2025

Although there is some evidence of an association between Alzheimer's disease polygenic risk score (AD PRS) and cognitive function, limited validations have been performed in large populations. We investigated the relationship AD PRS function UK Biobank over 276,000 participants further validated Disease Neuroimaging Initiative (ADNI) sample. developed (excluded APOE variants) middle age (age ranged 39–72, mean 57 years) European ancestries by LDpred2. To validate internally Biobank, we linearly regressed standardized on continuous with at test, sex, genotyping array, first 10 principal components genotyping, smoking, education years, body mass index, apolipoprotein E gene ε4 (APOE4) allele dosages. associations externally, ran linear mixed effects model ADNI sample free dementia 55–91, 73), including similar covariates as fixed participants' IDs random effect. Stratification age, APOE4 carrier status, status (cognitively normal or mild impairment) was also investigated. Our study both midlife late-life observational cohorts. not all measures were significantly associated PRS, non-verbal fluid reasoning (matrix pattern completion, β = − 0.022, P 0.003), processing speed (such symbol digit substitution, 0.017, 1.08E−05), short-term memory attention pairs matching, 0.014, 1.66E−10), reaction time (β 0.010, 1.19E−06) inversely increasing Biobank. Higher likelihood impairment higher individuals assessment scale 0.079, 0.02). In summary, confirmed that poorer a risk, suggested potential utility identifying those who may be for decline.

Язык: Английский

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease DOI
Jianping Jia, Yuye Ning, Meiling Chen

и другие.

New England Journal of Medicine, Год журнала: 2024, Номер 390(8), С. 712 - 722

Опубликована: Фев. 21, 2024

Biomarker changes that occur in the period between normal cognition and diagnosis of sporadic Alzheimer's disease have not been extensively investigated longitudinal studies.

Язык: Английский

Процитировано

163
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease DOI
Dallas P. Veitch, Michael W. Weiner,

Paul Aisen

и другие.

Alzheimer s & Dementia, Год журнала: 2021, Номер 18(4), С. 824 - 857

Опубликована: Сен. 28, 2021

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 2020.

Язык: Английский

Процитировано

112
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4 DOI
Michael W. Weiner, Dallas P. Veitch,

Melanie J. Miller

и другие.

Alzheimer s & Dementia, Год журнала: 2022, Номер 19(1), С. 307 - 317

Опубликована: Окт. 9, 2022

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for disease (AD) clinical trials. To improve generalizability, ADNI4 enroll 50‐60% of its new participants from underrepresented populations (URPs) using biofluid and digital technologies. has received funding the National Institute on Aging beginning September 2022. Methods will recruit URPs community‐engaged approaches. An online portal screen 20,000 participants, 4000 whom (50‐60% URPs) be tested plasma APOE . From this, 500 undergo in‐clinic assessment joining ADNI3 rollover participants. Remaining (∼3500) longitudinal cognitive testing. add MRI sequences PET tracers. Project 1 optimize in AD Results Discussion generalizability results, use remote blood screening, continue providing clinical, biomarker, autopsy data investigators.

Язык: Английский

Процитировано

87
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology DOI

Hui-Fu Wang,

Wei Zhang, Edmund T. Rolls

и другие.

EBioMedicine, Год журнала: 2022, Номер 86, С. 104336 - 104336

Опубликована: Ноя. 7, 2022

Язык: Английский

Процитировано

58
Alzheimer’s Disease Seen through the Eye: Ocular Alterations and Neurodegeneration DOI Open Access
Daniel Romaus‐Sanjurjo, Uxía Regueiro,

Maite López‐López

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(5), С. 2486 - 2486

Опубликована: Фев. 24, 2022

Alzheimer's Disease (AD) is one of the main neurodegenerative diseases worldwide. Unfortunately, AD shares many similarities with other dementias at early stages, which impedes an accurate premortem diagnosis. Therefore, it urgent to find biomarkers allow for diagnosis disease. There increasing scientific evidence highlighting between eye and structures CNS, suggesting that knowledge acquired in research could be useful AD. For example, retina optic nerve are considered part central nervous system, their damage can result retrograde anterograde axon degeneration, as well abnormal protein aggregation. In anterior segment, aqueous humor tear film may comparable cerebrospinal fluid. Both fluids enriched molecules potential biomarkers. Indeed, pathophysiology AD, characterized by cerebral deposits amyloid-beta (Aβ) tau protein, also present eyes patients, besides numerous structural functional changes observed structure eyes. all this suggests ocular have used either predictive values assessment or diagnostic tools.

Язык: Английский

Процитировано

44
Finding new and better treatments for psychiatric disorders DOI Creative Commons
Steven M. Paul, William Z. Potter

Neuropsychopharmacology, Год журнала: 2023, Номер 49(1), С. 3 - 9

Опубликована: Авг. 15, 2023

Abstract In contrast to most fields of medicine, progress discover and develop new improved psychiatric drugs has been slow disappointing. The vast majority currently prescribed treat schizophrenia, mood anxiety disorders are arguably no more effective than the first generation introduced well over 50 years ago. With only a few exceptions current work via same fundamental mechanisms action as first-generation agents. Here we describe reasons for this outline number areas research that involve greater reliance on experimental therapeutics utilizing recent advances in neuroscience better understand disease biology. We exemplify potential impact these focus with several examples novel agents have emerged which support our optimism newer, tolerated agents, horizon. Together existing newer could offer markedly functional outcomes millions people still disabled by disorders.

Язык: Английский

Процитировано

40
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022 DOI Creative Commons
Dallas P. Veitch, Michael W. Weiner,

Melanie J. Miller

и другие.

Alzheimer s & Dementia, Год журнала: 2023, Номер 20(1), С. 652 - 694

Опубликована: Сен. 12, 2023

The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, biofluid samples. We used conventional search methods identify 1459 publications from 2021 2022 using data/samples reviewed 291 impactful studies. This review details how studies improved progression understanding trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, modeling trials plasma biomarkers like phosphorylated tau showed promise for use. Biomarkers amyloid beta, tau, neurodegeneration, inflammation, others were prognostic with individualized prediction algorithms available online. Studies supported the cascade, emphasized importance neuroinflammation, detailed widespread heterogeneity disease, linked genetic vascular risk, co-pathologies, sex, resilience. Biological subtypes consistently observed. Generalizability results is limited by lack cohort diversity, an issue ADNI-4 address enrolling a diverse cohort.

Язык: Английский

Процитировано

40
Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer’s disease? DOI Creative Commons
Sophia Mirkin, Benedict C. Albensi

Frontiers in Aging Neuroscience, Год журнала: 2023, Номер 15

Опубликована: Апрель 18, 2023

Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that affects memory, thinking, behavior, and other cognitive functions. Although there no cure, detecting AD early important for the development of therapeutic plan care may preserve function prevent irreversible damage. Neuroimaging, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission (PET), has served critical tool in establishing diagnostic indicators during preclinical stage. However, neuroimaging technology quickly advances, challenge analyzing interpreting vast amounts brain data. Given these limitations, great interest using artificial Intelligence (AI) to assist this process. AI introduces limitless possibilities future diagnosis AD, yet still resistance from healthcare community incorporate clinical setting. The goal review answer question whether should be used conjunction with AD. To question, possible benefits disadvantages are discussed. main advantages its potential improve accuracy, efficiency radiographic data, reduce physician burnout, advance precision medicine. include generalization data shortage, lack vivo gold standard, skepticism medical community, bias, concerns over patient information, privacy, safety. challenges present fundamental must addressed when time comes, it would unethical not use if can health outcome.

Язык: Английский

Процитировано

30
Sex and gender differences in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis: A narrative review DOI
Alessandra Nicoletti, Roberta Baschi, Calogero Edoardo Cicero

и другие.

Mechanisms of Ageing and Development, Год журнала: 2023, Номер 212, С. 111821 - 111821

Опубликована: Апрель 30, 2023

Язык: Английский

Процитировано

28
Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions DOI Creative Commons
Jessica Alber, Femke H. Bouwman, Jurre den Haan

и другие.

Alzheimer s & Dementia, Год журнала: 2023, Номер 20(1), С. 728 - 740

Опубликована: Ноя. 2, 2023

Abstract There is emerging evidence that amyloid beta protein (Aβ) and tau‐related lesions in the retina are associated with Alzheimer's disease (AD). Aβ hyperphosphorylated (p)‐tau deposits have been described were small spots visualized by vivo imaging techniques as well degeneration of retina. These changes correlate brain deposition determined histological quantification, positron emission tomography (PET) or clinical diagnosis AD. However, literature not coherent on these histopathological findings. One important reason for this variability methods interpretation findings across different studies. In perspective, we indicate critical methodological deviations among groups suggest a roadmap moving forward how to harmonize (i) histopathologic examination retinal tissue; (ii) methods, devices, algorithms; (iii) inclusion/exclusion criteria studies aiming at biomarker validation.

Язык: Английский

Процитировано

28